The growth potential of two human prostatic cell lines (PC3 and DU145) can be significantly and dose dependently inhibited by 5-alpha reductase inhibition (finasteride) and antiandrogens (cyproterone acetate and hydroxyflutamide). The complex, growth-promoting network of the prostatic epithelium, which includes both steroidal and peptidic factors, may indicate the existence in human prostatic cancer cells of autocrine loops involved in the production of dihydrotestosterone. The outcome of our in vitro experiments may favor the in vivo use of therapies that reduce androgenic production or action in all stages of prostatic carcinoma. Antiandrogens and 5-alpha reductase inhibition, which shows limited side effects, can be effective supplements to other stage-selective treatments.
ANTIANDROGENS AND 5-ALPHA REDUCTASE INHIBITION OF THE PROLIFERATION RATE IN PC3 AND DU145 HUMAN PROSTATIC-CANCER CELL-LINES
BOLOGNA M;BIORDI, ASSUNTA LEDA;VICENTINI, Carlo
1992-01-01
Abstract
The growth potential of two human prostatic cell lines (PC3 and DU145) can be significantly and dose dependently inhibited by 5-alpha reductase inhibition (finasteride) and antiandrogens (cyproterone acetate and hydroxyflutamide). The complex, growth-promoting network of the prostatic epithelium, which includes both steroidal and peptidic factors, may indicate the existence in human prostatic cancer cells of autocrine loops involved in the production of dihydrotestosterone. The outcome of our in vitro experiments may favor the in vivo use of therapies that reduce androgenic production or action in all stages of prostatic carcinoma. Antiandrogens and 5-alpha reductase inhibition, which shows limited side effects, can be effective supplements to other stage-selective treatments.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
